Miastenia gravis y su asociación con trastornos linfoproliferativos: casos clínicos
Author
dc.contributor.author
Cea Muñoz, Gabriel
Author
dc.contributor.author
Gallardo V., Andrés
Author
dc.contributor.author
Cabrera Contreras, María Elena
Admission date
dc.date.accessioned
2018-05-14T16:51:22Z
Available date
dc.date.available
2018-05-14T16:51:22Z
Publication date
dc.date.issued
2017
Cita de ítem
dc.identifier.citation
Rev Med Chile 2017; 145: 1626-1630
es_ES
Identifier
dc.identifier.issn
0717-6163
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/147699
Abstract
dc.description.abstract
Myasthenia gravis (MG) is a rare autoimmune disease of the neuromuscular
junction. It is characterized by variable weakness and excessive fatigability
of skeletal muscles. In the last few years, numerous reports have been published
showing the association between autoimmune diseases, such as systemic
erythematous lupus or rheumatoid arthritis, with lymphoid neoplasias. The
association between MG and lymphoid neoplasia seems to be less frequent. To
analyze this association we reviewed the MG patients in the Department of
Neurology, Hospital Salvador of Santiago, Chile. During a three-year period we
identified four patients who developed different lymphoproliferative disorders:
two with B-cell lymphoma, one with chronic lymphocytic leukaemia and one
plasmacytoma with an associated amyloidosis. The MG was generalized but
mild, all cases classified as type IIa according to the definition proposed by the
MG Foundation of America. The neoplasia appeared two to 36 years after the
onset of MG. These cases provide additional evidence of the association between
MG and lymphoproliferative disorders.